Compare BOF & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOF | ECOR |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 50.0M |
| IPO Year | 2023 | 2018 |
| Metric | BOF | ECOR |
|---|---|---|
| Price | $3.39 | $5.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 61.7K | 58.3K |
| Earning Date | 05-14-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.36 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,184,018.00 | ★ $32,032,000.00 |
| Revenue This Year | N/A | $34.03 |
| Revenue Next Year | N/A | $30.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 258.20 | 27.20 |
| 52 Week Low | $1.53 | $4.16 |
| 52 Week High | $4.95 | $8.55 |
| Indicator | BOF | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 41.54 |
| Support Level | $2.79 | $4.66 |
| Resistance Level | $3.47 | $7.87 |
| Average True Range (ATR) | 0.26 | 0.63 |
| MACD | -0.06 | -0.10 |
| Stochastic Oscillator | 3.16 | 16.18 |
Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.